Journal article

The endocannabinoidome in neuropsychiatry: Opportunities and potential risks

Gerwyn Morris, Ken Walder, Stefan Kloiber, Paul Amminger, Michael Berk, Chiara C Bortolasci, Michael Maes, Basant K Puri, Andre F Carvalho

PHARMACOLOGICAL RESEARCH | ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD | Published : 2021

Abstract

The endocannabinoid system (ECS) comprises two cognate endocannabinoid receptors referred to as CB1R and CB2R. ECS dysregulation is apparent in neurodegenerative/neuro-psychiatric disorders including but not limited to schizophrenia, major depressive disorder and potentially bipolar disorder. The aim of this paper is to review mechanisms whereby both receptors may interact with neuro-immune and neuro-oxidative pathways, which play a pathophysiological role in these disorders. CB1R is located in the presynaptic terminals of GABAergic, glutamatergic, cholinergic, noradrenergic and serotonergic neurons where it regulates the retrograde suppression of neurotransmission. CB1R plays a key role in ..

View full abstract

University of Melbourne Researchers